Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2023-04-25 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
北京双鹭药业股份有限公司监事会对公司2022内部控制评价报告的意见
Audit Report / Information Classification · 95% confidence The document is an opinion statement from the Supervisory Board regarding the company's 2022 internal control evaluation report. It references regulatory guidelines and confirms the effectiveness of internal controls for the year 2022. The document is short (482 characters) and does not contain detailed financial data or the full internal control report itself, but rather an opinion on it. This fits the category of an Audit Report / Information (AR), as it relates to internal control evaluation and audit-related oversight, not a full annual report or other types. Therefore, the classification is AR with high confidence. FY 2022
2023-04-25 Chinese
北京双鹭药业股份有限公司关于获得注射用伏立康唑药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Beijing Shuanglu Pharmaceutical Co., Ltd. regarding the approval of a drug registration certificate for an injectable antifungal medication (Voriconazole). It includes details about the drug, regulatory approval by the National Medical Products Administration, and the impact on the company. The document is short (1389 characters) and serves as a regulatory announcement about a product approval rather than a financial report or detailed corporate filing. It does not contain financial statements, management discussion, or shareholder voting results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-04-10 Chinese
北京双鹭药业股份有限公司关于公司持股控股股东、高管误操作导致违规减持股份并致歉的公告
Director's Dealing Classification · 95% confidence The document is an announcement from Beijing Shuanglu Pharmaceutical Co., Ltd. regarding a violation caused by a controlling shareholder and senior management's inadvertent stock reduction (misoperation leading to unauthorized share sale). It details the shareholding before and after the incident, the regulatory rules violated, and an apology statement. There is no financial data, no report attached or referenced as being published, and no mention of a formal report filing. The content is about insider share transactions and compliance with disclosure rules. This fits best under 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives, including violations or insider trades.
2023-03-27 Chinese
北京双鹭药业股份有限公司关于获得达格列净片药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a drug registration certificate from the National Medical Products Administration. It details the drug's basic information, approval status, and potential impact on the company. There are no financial statements, earnings data, or management discussions. The document is relatively short (1489 characters) and serves as an official announcement of a regulatory approval event rather than a financial or management report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-03-22 Chinese
北京双鹭药业股份有限公司关于公司第二大股东减持计划数量过半的进展公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement from Beijing SL Pharmaceutical Co., Ltd. regarding the progress of a share reduction plan by the company's second largest shareholder. It details the number of shares reduced, the methods of reduction, dates, prices, and the shareholder's holdings before and after the reduction. It references compliance with securities laws and stock exchange rules. The content focuses on a shareholder's reduction in holdings and the progress of that plan, which fits the definition of a Major Shareholding Notification (MRQ) as it reports changes in significant share ownership levels. The document length is short (1489 characters) and contains detailed data about shareholding changes, not just a brief notice or a report publication announcement. Therefore, the appropriate classification is MRQ with high confidence.
2023-03-16 Chinese
北京双鹭药业股份有限公司关于公司第二大股东可交债换股及减持导致持股比例变动超过5%的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a detailed announcement about changes in shareholding by the company's second largest shareholder, including specifics on share reduction through convertible bonds and stock sales. It includes precise shareholding percentages before and after the change, dates, and compliance with securities laws. This type of document is a notification of a major shareholding change, as it reports a shareholding change exceeding 5%. It is not a financial report, earnings release, or management report, nor is it a proxy or voting announcement. It fits the definition of Major Shareholding Notification (MRQ). The document length and content confirm it is not a brief announcement or a certification but a substantive disclosure of shareholding changes.
2023-03-16 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.